Prime Medicine $175 million IPO
The shares are listed on the Nasdaq Global Market
Davis Polk advised the joint book-running managers in connection with the upsized initial public offering of 10,294,118 shares of common stock of Prime Medicine, Inc. at $17.00 per share for total gross proceeds of approximately $175 million. The common stock is listed on the Nasdaq Global Market under the symbol “PRME.”
Prime Medicine is a biotechnology company committed to delivering a new class of differentiated, one-time, curative genetic therapies to address the widest spectrum of diseases. The company is deploying prime editing technology, a versatile, precise, efficient and broad gene editing technology, which is designed to make only the right edit at the right position within a gene.
The Davis Polk corporate team included partner Richard D. Truesdell Jr., counsel Alain Kuyumjian and associate Tomer Magid. Partner David R. Bauer and associates Brette L. Trost and Annie Xie provided intellectual property advice. The tax team included counsel Tracy L. Matlock and associate Justin Corvino. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.